Does oxygen saturation or distance walked predict rehospitalization in heart failure?

Journal of Cardiovascular Nursing

Volumn 23, Issue 4, 2008, Pages 349-356

  Howie Esquivel, Jill ^a   Dracup, Kathleen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anemia; Heart failure; Oxygenation; Sex

Indexed keywords

OXYGEN;

ADULT; AGED; ANALYSIS OF VARIANCE; ANEMIA; ARTICLE; BLOOD; BLOOD GAS ANALYSIS; DAILY LIFE ACTIVITY; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HOSPITAL READMISSION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NURSING ASSESSMENT; PATHOPHYSIOLOGY; PILOT STUDY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; SOCIOECONOMICS; STATISTICS; UNITED STATES; WALKING;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANEMIA; BLOOD GAS ANALYSIS; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NURSING ASSESSMENT; OXYGEN; PATIENT READMISSION; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SAN FRANCISCO; SEX DISTRIBUTION; SOCIOECONOMIC FACTORS; WALKING;

EID: 54049145583     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/01.JCN.0000317434.29339.14     Document Type: Article

References (28)

1. AHA. 2007 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2007.
2. Ward C. The need for palliative care in the management of heart failure. Heart. 2002;87:294-298.
3. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157:99-104.
4. Vinson JM, Rich MW, Sperry JC, Shah AS, McNamara T. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc. 1990;38:1290-1295.
5. Fonarow GC, Abraham WT, Albert NM, et al; OPTIMIZE-HF Investigators and Hospitals. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007;297(1):61-70.
6. Opasich C, Tavazzi L, Lucci D, et al. Comparison of one-year outcome in women versus men with chronic congestive heart failure. Am J Cardiol. 2000;86:353-357.
7. Kosiborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM. The prognostic importance of anemia in patients with heart failure. Am J Med. 2003;114:112-119.
8. Krumholz HM, Chen YT, Wang Y, Vaccarino V, Radford MJ, Horwitz RI. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J. 2000;139(1 pt 1):72-77.
9. Costanzo MR, Augustine S, Bourge R, et al. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation. 1995;92(12):3593-3612.
10. Kubo SH, Ormaza SM, Francis GS, et al. Trends in patient selection for heart transplantation. J Am Coll Cardiol. 1993;21(4):975-981.
11. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83(3):778-786.
12. Chelimsky-Fallick C, Stevenson LW, Lem V, Whipp BJ. Excessive oxygen deficit during low-level exercise in heart failure. Am J Cardiol. 1995;76(11):799-802.
13. Cleland JG, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet. 2003;362:14-21.
14. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132:919-923.
15. Majahalme SK, Baruch L, Aknay N, et al. Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial). Am J Cardiol. 2005;95:529-532.
16. Koelling TM, Chen RS, Lubwama RN, L'Italien GJ, Eagle KA. The expanding national burden of heart failure in the United States: the influence of heart failure in women. Am Heart J. 2004;147:74-78.
17. Wexler D, Silverberg D, Sheps D, et al. Prevalence of anemia in patients admitted to hospital with a primary diagnosis of congestive heart failure. Int J Cardiol. 2004;96:79-87.
18. Felker GM, Gattis WA, Leimberger JD, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol. 2003;92:625-628.
19. Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation. 2005;112:1121-1127.
20. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitali-zations. J Am Coll Cardiol. 2000;35:1737-1744.
21. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis. 1997;30:S192-S240.
22. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775-1780.
23. Silverberg DS, Wexler D, Blum M, et al. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitali-zation. Clin Nephrol. 2002;58:S37-S45.
24. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003;18:141-146.
25. Lucas C, Stevenson LW, Johnson W, et al. The 6-min walk and peak oxygen consumption in advanced heart failure: aerobic capacity and survival. Am Heart J. 1999;138:618-624.
26. Roul G, Germain P, Bareiss P. Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure? Am Heart J. 1998;136:449-457.
27. Opasich C, Pinna GD, Mazza A, et al. Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice? Eur Heart J. 2001;22:488-496.
28. Bittner V. Determining prognosis in congestive heart failure: role of the 6-minute walk test. Am Heart J. 1999; 138:593-596.